$1.13
+0.04 (+3.67%)
Open$1.08
Previous Close$1.09
Day High$1.14
Day Low$1.02
52W High$4.19
52W Low$1.07
Volume—
Avg Volume97.7K
Market Cap81.40M
P/E Ratio—
EPS$-1.65
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+2,590.3% upside
Current
$1.13
$1.13
Target
$30.40
$30.40
$22.94
$30.40 avg
$39.68
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 5.94M | 24.88M | 53.29M |
| Net Income | -207,405,147 | -1,320,959,060 | -9,463,863 |
| Profit Margin | -3,492.3% | -5,603.4% | -17.8% |
| EBITDA | -149,501,370 | -1,395,170,020 | -11,859,784 |
| Free Cash Flow | — | — | -9,841,834 |
| Rev Growth | +183.3% | -45.3% | -6.8% |
| Debt/Equity | 10.79 | 2.17 | 0.20 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $295.03 | +0.20% | 50.3 | 520.47B |
| AMGN | Amgen Inc | $465.67 | -0.30% | 26.9 | 252.64B |
| GILD | Gilead Sciences Inc | $168.08 | +0.08% | — | 208.95B |
| VRTX | Vertex Pharmaceuticals Inc | $538.60 | -0.74% | 33.9 | 134.82B |
| REGN | Regeneron Pharmaceuticals | $955.47 | +0.45% | 20.4 | 98.38B |
| ALNY | Alnylam Pharmaceuticals Inc | $165.04 | +5.36% | 7.7 | 20.98B |